Taken together the data from this study suggested a “window-of-opportunity” when CTLA-4 expression on Treg cells was likely to be most critical in having an effect tantamount to ameliorating the clinical symptoms of RA. This evidence concerns the gene CTLA4 and rheumatoid arthritis.